secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pelthos Therapeutics Inc. (PTHS)
CIK:        0001919246
Form:       8-K
Filed at:   2025-11-07T23:59:59+00:00
Accession:  0001753926-25-001715
Event type: other_material
Sentiment:  neutral
Materiality: 0.80
Item codes: 1.01, 2.03, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pelthos raises $18M via convertible notes; acquires Xepi from Biofrontera
-------------------------------------------------------------------------

- Issued $18.0M aggregate 8.5% senior secured convertible notes due Nov 2027; conversion price $34.442/sh (adjustable to $29.73 on shareholder approval).
- Acquired Xepi (ozenoxacin) cream from Biofrontera for up to $10M: $3M cash upfront, $1M conditional, $6M milestone payments.
- Entered Ferrer License Agreement for exclusive manufacture/commercialization of Xepi in US; 12-year initial term.
- Granted investors 5% royalty on Xepi net sales and rights to Sato/ZELSUVMI milestone payments under convertible note.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1919246/000175392625001715/0001753926-25-001715-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1919246/000175392625001715/g084989_8k.htm
  HTML page:      https://secwatch.observer/filing/0001753926-25-001715

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer